3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
20
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
2
Retinoblastoma
2
Lung Neoplasms
2
Esophageal Neoplasms
2
Uterine Cervical Neoplasms
1
Sjogren's Syndrome
1
Scleroderma, Systemic
1
Retinal Neoplasms
1
Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)
1
Recurrence
1
Psoriasis
1
Ovarian Neoplasms
1
Ovarian Cancer Recurrent
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC
1
Multiple Sclerosis
1
Melanoma
1
Lymphatic Metastasis
1
Lupus Erythematosus, Systemic
1
Inflammatory Bowel Diseases
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Dermatomyositis
1
Crohn Disease
1
Colorectal Neoplasms
1
Interventions
Cyclophosphamide
51
fludarabine
37
Dexamethasone
35
venetoclax
30
pembrolizumab
25
Rituximab
20
pomalidomide
18
Lenalidomide
17
Gemcitabine
17
fludarabine phosphate
15
Etoposide
14
Cytarabine
13
daratumumab
12
carfilzomib
11
Temozolomide
11
Injections
10
Calcium Dobesilate
10
glofitamab
9
Nivolumab
9
Cisplatin
9
Bortezomib
9
Azacitidine
9
selinexor
8
Vincristine
8
Immunotherapy, Adoptive
8
obinutuzumab
7
cemiplimab
7
Drug Therapy
7
Carboplatin
7
zanubrutinib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Platinum Compounds
×
1 year
×
Clear all
NCT07340164
2026-04-20
TROY
Yonsei University
Phase 2
Recruiting
116 enrolled